GAMMA Investing LLC Decreases Stake in Hims & Hers Health, Inc. $HIMS

GAMMA Investing LLC reduced its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 24.9% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,862 shares of the company’s stock after selling 1,281 shares during the period. GAMMA Investing LLC’s holdings in Hims & Hers Health were worth $193,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in the company. Smartleaf Asset Management LLC raised its stake in Hims & Hers Health by 15.7% in the 1st quarter. Smartleaf Asset Management LLC now owns 1,672 shares of the company’s stock worth $49,000 after acquiring an additional 227 shares during the last quarter. Allworth Financial LP increased its holdings in shares of Hims & Hers Health by 20.0% in the first quarter. Allworth Financial LP now owns 2,006 shares of the company’s stock valued at $56,000 after purchasing an additional 334 shares during the period. Signaturefd LLC raised its stake in shares of Hims & Hers Health by 17.7% in the first quarter. Signaturefd LLC now owns 2,586 shares of the company’s stock worth $76,000 after purchasing an additional 388 shares during the last quarter. Kilter Group LLC lifted its holdings in shares of Hims & Hers Health by 1.0% during the first quarter. Kilter Group LLC now owns 43,989 shares of the company’s stock worth $1,300,000 after purchasing an additional 450 shares during the period. Finally, Larson Financial Group LLC boosted its position in Hims & Hers Health by 47.7% in the first quarter. Larson Financial Group LLC now owns 1,419 shares of the company’s stock valued at $42,000 after buying an additional 458 shares during the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Patrick Harrison Carroll sold 10,021 shares of the company’s stock in a transaction that occurred on Wednesday, September 17th. The stock was sold at an average price of $50.50, for a total transaction of $506,060.50. Following the completion of the transaction, the insider directly owned 169,940 shares of the company’s stock, valued at $8,581,970. This represents a 5.57% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Irene Becklund sold 8,410 shares of the stock in a transaction that occurred on Wednesday, September 17th. The shares were sold at an average price of $50.50, for a total value of $424,705.00. Following the transaction, the insider owned 1,418 shares in the company, valued at $71,609. This trade represents a 85.57% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,535,090 shares of company stock valued at $78,294,662. 17.71% of the stock is owned by insiders.

Wall Street Analyst Weigh In

HIMS has been the subject of a number of recent research reports. UBS Group set a $30.00 price target on shares of Hims & Hers Health in a research report on Monday, June 23rd. Zacks Research cut shares of Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 19th. Truist Financial lowered their price target on shares of Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating on the stock in a report on Monday, August 18th. Wall Street Zen downgraded Hims & Hers Health from a “buy” rating to a “hold” rating in a research report on Monday, July 28th. Finally, Citigroup reissued a “sell” rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Two equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Reduce” and a consensus target price of $38.92.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS opened at $58.35 on Monday. The company has a market capitalization of $13.19 billion, a PE ratio of 72.93, a price-to-earnings-growth ratio of 3.94 and a beta of 2.14. The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98. The company’s fifty day moving average price is $51.22 and its 200 day moving average price is $46.54. Hims & Hers Health, Inc. has a 1 year low of $16.05 and a 1 year high of $72.98.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The firm had revenue of $544.83 million during the quarter, compared to analyst estimates of $550.06 million. During the same quarter last year, the company posted $0.06 EPS. The company’s revenue was up 72.6% on a year-over-year basis. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, research analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.